Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - Adaptive Biotechnologies reported a quarterly loss of $0.22 per share, better than the Zacks Consensus Estimate of a loss of $0.30, and an improvement from a loss of $0.35 per share a year ago, resulting in an earnings surprise of 26.67% [1] - The company achieved revenues of $46.44 million for the quarter ended September 2024, exceeding the Zacks Consensus Estimate by 14.41% and showing a year-over-year increase from $37.92 million [2] - The stock has gained approximately 17.4% year-to-date, underperforming the S&P 500's gain of 24.3% [3] Earnings Outlook - The future performance of Adaptive Biotechnologies' stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - Current consensus EPS estimate for the upcoming quarter is -$0.30 on revenues of $46.34 million, and for the current fiscal year, it is -$1.23 on revenues of $172.06 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Adaptive Biotechnologies belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]